胸腺肽联合标准化疗治疗纵膈淋巴结核临床疗效分析

Analysis of curative effect of thymosin combined with standard chemotherapy in the treatment of patients with mediastinal lymphatic tuberculosis

目的分析标准化化疗加胸腺肽治疗纵隔淋巴结核的临床疗效。方法将42例纵膈淋巴结核患者随机分组为胸腺肽干预组及对照组,其中干预组19例,对照组23例,治疗中有2组退出,对照组采用6HRZE/9HRE方案。干预组在6HRZE/9HRE方案基础上加用胸腺肽100 mg,静滴隔日1次,治疗3个月,观察临床症状缓解时间并两组间比较。治疗3个月、6个月观察淋巴结缩小情况并两组间比较。结果在治疗临床症状缓解(症状消失或缓解)时间比较干预组优于对照组,差异有显著性。干预组在治疗3个月及治疗6个月淋巴结缩小好转率均优于对照组,P<0.05。结论纵膈淋巴结核在标准化抗结核化疗基础上加用免疫调节剂胸腺肽治疗可调节机体的免疫功能,从而达到更有效的治疗效果。

Objective To analyze the clinical curative effect of thymosin combined with standard chemotherapy in the treatment of patients with mediastinal lymphatic tuberculosis. Methods 42 patients with mediastinal lymphatic tuberculosis were randomly divided in- to the thymosin intervention group （ n = 19） and the control group （n = 23）. All patients were given 6HRZE/9HRE plan, and the inter- vention group was additionally treated with 100 mg of thymosin, intravenous drip once every other day for 3 months. The clinical curative effect was compared between the two groups. Results The elinieal remission time was obviously shorter in the intervention group than in the control group with significant difference. The improvement of lymph nodes shrink was more pronounced in the intervention group than in the eontrol group. Conclusion The standardized anti-tuberculosis chemotherapy eombined with immune regulator thymosin therapy can regulate the body＇s immune function of patients with mediastinal lymphatie tuberculosis. Therefore, it has positive significance on clinical application.